Condition: Alagille Syndrome · Progressive Familial Intrahepatic Cholestasis · Sponsor: Mirum Pharmaceuticals, Inc.
The objective of this 5-year, prospective, observational cohort study is to evaluate the long-term safety and clinical outcomes of patients with Alagille syndrome (ALGS) or Progressive familial intrahepatic cholestasis (PFIC) treated with Livmarli.
This description comes directly from the study's public registry record.
Clinical Trials Mirum · +16506674085 · Clinical Trials <clinicaltrials@mirumpharma.com>;
Always discuss trial participation with your own doctor first.
| Children's Hospital Los Angeles CHLA | Los Angeles, California, United States | Recruiting |
| Section of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics and the Digestive Health Institute, Children's Hospital of Colorado and University of Colorado | Aurora, Colorado, United States | Recruiting |
| Children's Healthcare of Atlanta - Emory University School of Medicine | Atlanta, Georgia, United States | Recruiting |
| Children's Mercy Kansas City, Department of Gastroenterology, Section of Hepatology | Kansas City, Missouri, United States | Recruiting |
| Oregon Health and Science University, Division of Pediatric Gastroenterology, Department of Pediatrics | Portland, Oregon, United States | Recruiting |
| Children's Hospital of Philadelphia | Philadelphia, Pennsylvania, United States | Recruiting |
| Children Hospital of Pittsburgh | Pittsburgh, Pennsylvania, United States | Recruiting |
| University of Utah, Division of Pediatric Gastroenterology, Hepatology and Nutrition | Salt Lake City, Utah, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06193928